Member Info for hahahehehoho

It should be indeed. very good news if true.

tom , not sure if any of it true or not tbh. surely rms holders can't be that stupid.

Hewho, if your comment alleviates your pain here and makes you feel bigger, then I agree with everything you said about me.

You fail to forget, Trevor Brown gave P2F to RMS on a platter, when Braveheart could quite easily of taken all of it. FACT

Without Trevor's action, there is a high probability RMS would be languishing at 0.3p range ...... and now you want him sacked. LOl and IMO.

Are you stupid? GDR are not going to release an RNS stating their test can't detect any new mutation.
Their best calculated bet is to say that they have already developed or are developing a new mutation test and this will be welcome news = SP rocketing upwards + genuine new hope and fresh start IMO.

If they are doing nothing about this mutation strain then good luck to all holders

If it is true and ungrateful RMS shareholders are trying to do a number on him, then they are stupid because they are sabotaging the company into self destruct mode. The SP has performed remarkably well from 0.3p this year so I don't see the problem of a placing at 1.2p. It just goes to show RMS investors want fast money in RMS because they know how volatile it is and have zero confidence in the board andwhere that 5 mill is going!

Alll this is quite entertaining all being said, but if any of that PDF is true, and no agreement can be reached and escalates further , King Trev will just suspend RMS....sending a big FU sign to all haters..because no-one messes with The King.

I'd say big bench is actually right for once. This should provide a necessary spike in the SP again.

IF GDR 's current test can dtect mutations, they literally have been given a second lifeline. Ncyt however,have test on the market for a new strain of COVID-19 and are currently developing two new RUO PCR tests for avian flu since last month.

My hunch is that Genedrive's should be doing some R+D into developing a new test. Things move fast and GDR need to move with the times.

Trevor Brown is the last person you'd want to peeve off since he has so much power at RMS.

If that pdf is true and they can't come up with a solution, RMS will probably be suspended and lawsuits will continue. BRH holders literally got free money in the way of 18 million big ones.

Leave King Trev alone. I would start to be accumulating small here if it keeps dropping. Whether or not the small trial result batches are successful or not at the end of Jan, the SP should be going up and there is money to be made here.

I am also sure King Trev will announce something regarding COVID mutations soon and this will boost the SP.

Anything is tradeable. For the right price I'd buy bull$h1t

I think novacyt must of been working on that new test for months. Clever guys.

Steady on Gloria. Novacyt only just released their new mutant test 7 days ago. I'm sure Genedrive are developing a new kind of test as we speak and should be announced to market soon this year. If not , then there must be a logical explanation why they had £3.5 last year , then raised £9m ...and now only have £5m left.

The bottom line is, Ncyt could of done a test with bead format and didn't. They could of also developed a LFT test but didn't. They stuck to not being too smart and have been rewarded on every step of the way.

Gloria, I don't think they have missed the boat with this mutant variation. It's up to GDR whether or not to ditch the old test and create a new or adapted one...then at least make an effort to get a sale.

You can never compare this to Ncyt. The CEO of Ncyt is too educated, too experienced and too savvy. Bottom line is , he can see the future and make bold decisions. Total respect. In life you get what you pay for.

I agree Karen. This is GDR's best shot of getting a sale. If they can't - there are no excuses as they don't need approvals in usa and have clearance to sell in Europe and s. Africa

I think the problem I think here is that people buy into gdr because of the low market cap and look at Ncyt and expect the same kind of sales performance. People will keep defending this company simply because it has a cheap market cap and is in a hot sector right now which is fairly understandable. However, life simply doesn't work that way where there are winners there must be losers.

This is basically GDRs second chance to get a significant sale.

None because no one has bought anything. If anything now would be a good time to issue an Rns to clear things up regarding mutations. Or even commence r+ d into a new test for mutations.